StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) stock

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.03 (-7.82%)

Close on Nov 17, 2026Market cap $1.29MP/E –Yield –

Scinai Immunotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Scinai Immunotherapeutics's R&D Expenses for the twelve months ending Dec 31, 2021 was $3.25M. For fiscal 2025 it was $2.37M, down 57.2% from the year before. The highest annual figure on record is $16.01M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.37M-57.2%
FY2024Dec 31, 2024$5.53M+6.2%
FY2023Dec 31, 2023$5.21M-9.6%
FY2022Dec 31, 2022$5.77M+77.4%
FY2021Dec 31, 2021$3.25M-79.7%
FY2020Dec 31, 2020$16.01M+195.6%
FY2017Dec 31, 2017$5.42M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023$1.45M+23.1%
Q1 FY2023Mar 31, 2023$2.00M–
Q2 FY2022Jun 30, 2022$1.97M–
Q1 FY2022Mar 31, 2022$1.16M–
Q4 FY2021Dec 31, 2021$1.18M–

More Scinai Immunotherapeutics figures

See a number that looks wrong?